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Abstract
Background: Several controversial matters still remain unresolved in the management of Takayasu’s arteritis, especially
after vascular intervention. First, a definitive diagnostic tool has not been established to assess disease activity correctly.
Second, the optimal medical regimen has not been established to prevent restenosis of the vascular lesion.
Surgical treatments have been rarely performed to relieve critical vascular stenosis in isolated pulmonary Takayasu’s
arteritis, but their postoperative courses on long-term follow-up periods have not been sufficiently reported.
Case Presentation: A 48-year-old man underwent a successful graft replacement for severe right main pulmonary
artery stenosis due to isolated pulmonary Takayasu’s arteritis. The patient had remained asymptomatic with no clinical
inflammatory signs under adequate anticoagulation therapy since then. However, stenosis of the prosthetic graft
accompanied by marked pulmonary hypertension was detected 18 months after surgery. Anti-inflammatory treatment
with only 5 mg/day of oral prednisolone was then implemented, and the stenosis remained unchanged with the
patient being stable for the next 16 months.
Conclusions: This is the first published case report that describes the actual clinical course with a long-term follow-up
period after surgery for isolated pulmonary Takayasu’s arteritis, including images of the stenosed prosthetic graft.
This case suggests that patients should be followed with multiple complementary diagnostic techniques on the
assumption that restenosis is highly possible and unpredictable even after surgery. Besides, sufficient anti-inflammatory
treatment should be applied as soon as possible after surgery no matter how inactive the disease appears to be,
although its optimal regimen especially during the inactive inflammatory phase needs to be further established.
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Background
Surgical treatments have been performed, albeit rarely,
to relieve critical vascular stenosis in isolated pulmonary
Takayasu’s arteritis (TA), a very rare TA subtype which
primarily involves pulmonary arteries (PAs) without any
systemic arterial lesions [1–4]. To our knowledge, 13
case reports, including our own report, have described 3
different types of surgical procedures: patch angioplasty
in 5 cases, bypass surgery accompanied with no resection
of the involved lesions in 2 cases, and graft replacement
accompanied with removal of the pathologic vessels in 6
cases. The surgical outcomes were satisfactory with no
mortality and no serious complications [1] (Table 1).
However, the postoperative courses on long-term
follow-up periods have not been sufficiently reported,
although TA is basically a chronic, progressive, and re-
lapsing disease and restenosis of the vascular lesion
occurs quite commonly [3, 5]. In 11 of those 13 cases,
the follow-up results were mentioned with relatively
short follow-up periods from 1 to 66 months (21.3 ±
21.5 months), and only 8 patients underwent imaging
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studies, e.g. either computed tomography (CT), mag-
netic resonance imaging, or angiography to evaluate the
patency of the surgical materials [1]. These imaging
studies revealed mild restenoses at the surgical sites
without clinical signs or symptoms in 4 of the patients
at as early as 3 months postoperatively. Those 4 cases
were all managed by patch angioplasty at the PA bifur-
cation, leaving the native vessel wall behind. No details
on their clinical courses after restenoses were described,
and also no actual images of the restenoses were
presented (Table 1).
Case Presentation
The patient had severe stenosis of unknown etiology in
the middle of the right main PA, accompanied by
marked pulmonary hypertension and dysfunction of the
right ventricle (RV) at age 48 (Fig. 1a, b). The existing
hemodynamic strains required endovascular or surgical
intervention to relieve the stenosis, and we chose sur-
gery, hoping to establish the diagnosis. We were con-
cerned about either local progression or spread to the
other area of this undiagnosed stenosis if the lesion was
left behind with patch angioplasty or bypass surgery.
Table 1 Summary of the surgery for isolated pulmonary TA
Pt Age (Y),
gender




Restenosis Immuno-suppression Author (’Y)
1 60 F Bifurcation Patch Pericardium 6 AG Yes Yes* Chauvaud (’87)
2 53 M Bifurcation Patch Pericardium 6 AG Yes - Dietl (’88)
3 57 M Rt Patch - - - - - Okubo (’88)
4 31 M Bifurcation Patch Dacron 18 AG Yes - Jakob (’90)
5 34 F Rt Grafting NA 13 - - - Lie (’96)
6 25 F Rt Grafting NA 25 - - - Lie (’96)
7 76 F Rt & Lt Bypass PTFE - - - - Sundt (’01)
8 63 F Rt & Lt Grafting Dacron 66 - - - Shikata (’04)
9 67 F Rt Patch Pericardium 3 AG Yes - Yamazaki (’05)
10 45 F Lt Bypass PTFE 60 AG No - Nakajima (’07)
11 48 M Rt Grafting Dacron 6 CT No No Fujita (’13)
12 59 M Rt & Lt Grafting PTFE 1.5 AG & CT No Yes† Hamamoto (’11)
13 51 F Rt & Lt Grafting PTFE 30 AG & CT No - Furtado (’12)
Pt: patient number, Y: year, M: male, F: female, Bifurcation: bifurcation of the main pulmonary artery trunk, Rt: right main pulmonary artery, Lt: left main
pulmonary artery, Patch: patch angioplasty, Grafting: graft replacement, Bypass: bypass surgery, PTFE: polytetrafluoroethylene, AG: angiography, CT: computed
tomography, *: glucocorticoid at unknown dosage, †: oral prednisolone at 20 mg/day, −: not available
Fig. 1 Chest CT images: (a, b) Before surgery, showing stenosis of the right PA (arrows); (c, d) At 6 months after surgery, showing the patent
grafts of the right PA (arrows); (e, f) At 18 months after surgery, showing the stenosis of the right PA graft (arrows); (g, h) At 34 months after
surgery, showing unchanged stenosis of the right PA graft (arrows)
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Thus, we decided to perform graft replacement with
total excision of the lesion, and an 18 mm Dacron graft
(TriplexR, Terumo Corporation, Japan) was anastomosed
in an end-to-end fashion behind the ascending aorta. He
was finally diagnosed as having isolated pulmonary TA
only by the pathological examination of the resected right
PA (Fig. 2), and began anticoagulation therapy with war-
farin to attain a target prothrombin time - international
normalized ratio (PT-INR) of 2.0 – 2.5 in addition to
aspirin at 100 mg/day. At the 6-month follow-up after sur-
gery, enhanced chest CT showed a patent graft (Fig. 1c, d),
and transthoracic echocardiography (TTE) demonstrated
normalized RV function [1]. The patient remained asymp-
tomatic since then, and was followed with laboratory tests
every 2 months, which showed no remarkable changes in
C-reactive protein (CRP) values of less than 0.5 mg/dl. He
had TTEs every 6 months, which demonstrated no abnor-
mality at his 12-month follow-up (Table 2).
However, TTE at the 18-month follow-up showed re-
markable pulmonary hypertension and RV dysfunction
with preserved left ventricle systolic function (Table 2).
Thus, enhanced chest CT was performed and revealed
severe stenosis of the right PA graft especially at the
anastomotic sites, surrounded by a circumferential ab-
normal shadow covering the full length of the graft
(Fig. 1e, f ). Peripheral PAs distal to the PA graft were
intact, and no other apparent abnormalities or changes
on the other chest and neck vessels were observed when
compared to that of the previous studies. Whole body
positron emission tomography with fluorine-18 fluoro-
deoxyglucose CT (FDG-PET) was then performed for
the first time and demonstrated high FDG uptake only
around the right PA graft, but no other abnormal uptake
by the other vessels was observed (Fig. 3a, b). The FDG-
PET result suggested that focal inflammation around the
graft was the most probable cause of the stenosis, al-
though CRP levels remained almost unchanged (Table 2).
Oral prednisolone at 10 mg/day was thus initiated, but
was reduced to 5 mg/day 2 months afterwards because of
its potential side effects, including facial edema, depressive
mood disorder, and mild liver dysfunction. The facial
edema persisted since then, but otherwise the patient
remained asymptomatic and did not consent to take
additional immunosuppressive agents. Repeated CTs,
TTEs, and laboratory tests at 24- and 30-month follow-
ups demonstrated no remarkable changes (Table 2).
However, the patient gradually complained of dyspnea on
exertion since then. An oral diuretic was added on suspi-
cion of exacerbating right heart strain, but the patient was
readmitted to the hospital due to worsening symptoms
31 months after surgery. TTE on re-admission revealed no
remarkable change compared to that of the previous stud-
ies, except for decreased right ventricular systolic pressure,
which seemed to be inconsistent with right heart failure but
rather indicated hypovolemia (Table 2). Indeed, cessation of
the diuretic and fluid replacement improved the patient’s
condition and symptoms rapidly. Re-catheterization and
subsequent angioplasty or re-surgery were thus offered, but
the patient refused any interventional procedures. The
patient also refused increasing the dose of prednisolone,
complaining of the still persisting facial edema.
After leaving the hospital, the patient’s physical condi-
tion remained stable on the same dosage of prednisol-
one. CT and TTE performed at the 34-month follow-up,
3 months after re-admission, showed no remarkable
change in the right PA graft stenosis and similar pul-
monary hypertension. Thus, the stenosis accompanied
Fig. 2 A section of the right PA, showing granulomatous
lymphoplasmacytic arteritis of the media with irregularly distributed
Langhans’ giant cells (arrows, hematoxylin and eosin, 100x)
Table 2 Pre- and postoperative laboratory and TTE findings
Pre 6M 12M 18M* 24M 31M† 34M
Laboratory findings
WBC (/μL) 7200 3900 6700 7100 4800 6200 2900
CRP (mg/dL) 0.26 0.18 0.16 0.35 0.09 0.21 0.26
ESR (mm/1hr) 10 6 - 1 - - -
PT-INR 0.99 2.09 2.42 2.42 1.85 2.27 2.13
TTE findings
TRPG (mmHg) 38 50 ND 77 64 30 71
RVSP (mmHg) 41 53 ND 80 72 33 74
PAPG (mmHg) - - - - 63 45 52
Tr Trivial Trivial None Trivial Trivial Trivial Trivial
EF (%) 67 63 59 69 64 71 61
TTE: transthoracic echocardiography, Pre: preoperatively, M: months after
surgery, *: detection of the restenosis, †: at readmission, WBC: white blood
cell, CRP: C-reactive protein, ESR: erythrocyte sedimentation ratio, PT-INR:
prothrombin time-international normalized ratio, TRPG: tricuspid regurgitation
pressure gradient, RVSP: right ventricular systolic pressure, PAPG: pressure
gradient between main and right pulmonary artery, Tr: tricuspid regurgitation,
EF: ejection fraction, ND: not detected, −: not available
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with pulmonary hypertension and RV dysfunction was
almost unchanged for as long as 16 months since its first
detection (Fig. 1g, h, and Table 2). Thereafter, contact
with the patient was lost.
Discussion
We can define 3 clinical pitfalls in this case, although the
definite etiology of the graft stenosis remained unestab-
lished and a longer follow-up period with repeated assess-
ment of the local inflammatory activity was desirable.
First, we should have taken into account the fact that
the inflammatory process in TA can remain active at a
subclinical level, no matter how inactive it appears to be
[4, 5, 7]. In addition, identifying such subclinical inflam-
mation prior to subsequent recurrence is very difficult,
because clinical, laboratory, and radiologic data do not
always correlate with each other [2–7]. CRP and erythro-
cyte sedimentation rate, which are generally used as safe
and non-invasive inflammatory surrogate markers, are not
always reliable [7–9]. Indeed, the stenosis of the right PA
graft had presumably progressed between 12 and
18 months after surgery in this case, but neither clinical
features nor laboratory tests alone could demonstrate this
on-going stenosis. Thus, CT was not performed after the
6-month follow-up, but if we had performed imaging
studies with either CT or magnetic resonance imaging
periodically, regardless of whether any signs for stenosis
were perceived or not, the stenosis might have been de-
tected at an earlier stage [9]. Moreover, FDG-PET would
have been of value for monitoring [9]. It could be useful
especially when the assessment of disease activity is diffi-
cult due to the absence of clinical features with absent or
low CRP elevation, because it can detect even subtle
inflammatory activity in the vessel walls with higher sensi-
tivity than CRP [4, 7]. If we had performed FDG-PET soon
after the surgery to examine the actual inflammatory
activity around the PAs, it might have encouraged us to
commence anti-inflammatory treatment earlier, although
the other clinical findings were incompatible with active
inflammation.
Second, anti-inflammatory treatment, starting no later
than the establishment of the pathological diagnosis of
TA, might have altered the clinical course [2, 6]. The
graft stenosis could occur due to any reason, especially
with pannus formation or thrombosis, but the FDG-PET
result suggested that the local inflammation was in-
volved in the graft stenosis. We did not initiate immuno-
suppression until discovery of the restenosis, assuming
that the graft replacement with entire resection of the
pathological PA wall could deprive the vasculitis of its
normal course of action. The fact that systemic inflam-
matory features were absent perioperatively and that the
above-mentioned 4 published cases with late restenoses
were all managed by patch angioplasty leaving the
pathological PA wall behind seemed to concur with our
speculation. But the total removal of the pathological
right PA wall was not guaranteed even with the patho-
logical examination of the surgical specimen. Moreover,
the absence of systemic inflammatory features should
Fig. 3 FDG-PET CT images at 18 months after surgery: (a) Abnormal
uptakes were detected only around the right PA graft; (b) No other
apparent abnormal uptake was detected on the other large vessels
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not have omitted immunosuppression, because systemic
clinical manifestations are usually rare or absent in iso-
lated pulmonary, in which the inflammatory process
involves only PAs [3, 4]. Besides, reliable and timely
evaluation of disease activity is difficult, and established
vascular stenosis cannot usually be reversed by medical
treatment alone [2, 3, 6]. Therefore, anti-inflammatory
treatment should have been considered as soon as
possible after surgery, regardless of the apparent clinical
inflammatory status [2].
Finally, another anti-inflammatory regimen with either
a higher-dose of glucocorticoids or combined with other
immunosuppressants might have resulted in a different
clinical course [2, 3, 6]. The current European League
Against Rheumatism (EULAR) recommendation pro-
poses an aggressive induction therapy for the manage-
ment of large vessel vasculitis, consisting of an initial
1 mg/kg oral prednisolone dose (maximum 60 mg/day)
for one month with subsequent tapering to 10–15 mg/
day for several months [9]. However, this recommenda-
tion does not mention in which condition this regimen
should be applied. This patient’s clinical condition at the
commencement of glucocorticoids was not suggestive of
active inflammatory status, which caused us to hesitate
in applying such a high dose of glucocorticoids. Attend-
ant adverse effects of them, particularly either increased
thrombogenecity or risk of infection, cannot be ignored
especially immediately after surgery [2, 4]. Actually, even
such a low initial dose, oral prednisolone of 10 mg/day
in this 72 kg-patient, was reduced to 5 mg/day due to its
known adverse effects. But we could have at least per-
formed FDG-PET repeatedly and considered additional
immunosuppressive agents, which can help to improve
disease control and facilitate reduction of the cumulative
glucocorticoid dose [2, 6, 9]. Besides, there are a few
case reports of isolated pulmonary TA, which demon-
strated decreased PA pressure after anti-inflammatory
treatment with high dose of glucocorticoids and additional
immunosuppressive agents, despite of unchanged sten-
otic lesions in imaging studies [6, 10]. Therefore, even
after the development of significant restenosis, suffi-
cient anti-inflammatory treatment might have been
worthwhile, although its optimal regimen has yet to be
defined.
Conclusion
This case suggests that patients after surgery for isolated
pulmonary TA should be followed with multiple com-
plementary diagnostic techniques, including CT, mag-
netic resonance imaging, and in particular, FDG-PET at
regular intervals, on the assumption that restenosis is
highly possible and unpredictable. Anticoagulation ther-
apy alone is insufficient to prevent restenosis, and suffi-
cient anti-inflammatory treatment should be applied as
soon as possible after surgery regardless of the apparent
inflammatory status, although the optimal regimen needs
to be further established.
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